Foundation Medicine has partnered with PMV Pharmaceuticals to develop FoundationOneCDx, a tissue-based genomic profiling test, as a companion diagnostic for PMV Pharma's rezatapopt (PC14586).
Rezatapopt is an investigational, first-in-class therapy for patients with locally advanced or metastatic solid tumors with a TP53 Y220C mutation. It is designed to stabilize p53 Y220C proteins. It is the subject of the ongoing registrational, tumor-agnostic PYNNACLE Phase II clinical trial, and has been granted the Fast Track designation by the FDA for treating patients with locally advanced or metastatic solid tumors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.